Objectives This study aimed to systematically review the use of cost-effectiveness (CE)
threshold for evaluating pharmacological interventions in Greece. Methods A systematic …

Background: The amount a government should be willing to invest in adopting new medical
treatments has long been under debate. With many countries using formal cost-effectiveness …

Objective To perform a first-time analysis of the cost-effectiveness (CE) literature on
chemotherapies, of all types, in cancer, in terms of trends and change over time, including …

Cost–effectiveness analysis is used to compare the costs and outcomes of alternative policy
options. Each resulting cost–effectiveness ratio represents the magnitude of additional …

Objectives We aimed to compare the use of cost-effectiveness analysis and cost-utility
analysis in health technology assessment in Poland. Methods We analyzed all the …

Abstract Purpose Targeted cancer therapies (TCTs) are drugs that specifically act on
molecular targets within the cancer cell, causing its regression and/or destruction. Although …

Background There is a debate on the added clinical value of new, expensive, anticancer
treatments. Among European decision makers, the relevance of commonly used end points …

Objectives To determine what thresholds are most often cited in the cost-effectiveness
literature for low-and middle-income countries (LMICs), given various recommendations …

Background: Price setting and reimbursement decisions regarding drugs are competence of
individual member states in Europe. These decisions involve important trade-offs between …

Objectives: Timely access to novel anticancer drugs is challenging and value frameworks
such as the European Society of Medical Oncology Magnitude of Clinical Benefit Scale …